Rivia is a Zurich-based data engine for clinical trial intelligence that builds a reusable intelligence layer to unify fragmented clinical trial data and enable AI-driven workflows.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $15 M | Mar, 2026 | series-a |
Frequently Asked Questions
Where is Rivia located?
Rivia is located in Zurich, Switzerland.
What industries does Rivia operate in?
Rivia operates in the following industries: healthtech, clinical trials, data infrastructure, artificial intelligence, biotech software.
How much total funding has Rivia raised?
Rivia has raised a total of $15,000,000.
Who are the investors in Rivia?
The investors in Rivia are: Earlybird, Speedinvest, Defiant, Amino Collective, Nina Capital.
Who are the founders of Rivia?
The founders of Rivia are: Tiago Kieliger, Erik Scalfaro.
What is Rivia?
Rivia is a clinical data platform designed for biopharma companies to centralize, visualize, and analyze their clinical trial data in real-time.
How does Rivia support clinical trial teams?
Rivia provides interactive dashboards and automated data integration, allowing clinical operations and medical monitoring teams to oversee safety, efficacy, and study progress more efficiently.
Who are the primary users of Rivia?
The platform is primarily used by biotechnology companies, pharmaceutical firms, and clinical research organizations to streamline their data management and decision-making processes.
Can Rivia integrate with different data sources?
Yes, Rivia is built to ingest and harmonize data from various sources such as electronic data capture systems, laboratories, and other clinical trial technology providers.
What are the main benefits of implementing Rivia?
Key benefits include reduced manual data cleaning, faster identification of safety signals, improved cross-functional collaboration, and more effective oversight of clinical development programs.